Sign in Sign up for free

Last updated: 18 June 2024 at 4:06pm EST

Brian Corvese Net Worth




The estimated Net Worth of Brian Corvese is at least $1.18 Million dollars as of 16 June 2021. Mr. Corvese owns over 22,471 units of Agenus Inc stock worth over $519,359 and over the last 17 years he sold AGEN stock worth over $0. In addition, he makes $662,141 as Independent Director at Agenus Inc.

Mr. Corvese AGEN stock SEC Form 4 insiders trading

Brian has made over 2 trades of the Agenus Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 22,471 units of AGEN stock worth $126,736 on 16 June 2021.

The largest trade he's ever made was exercising 22,471 units of Agenus Inc stock on 16 June 2021 worth over $126,736. On average, Brian trades about 1,677 units every 14 days since 2007. As of 16 June 2021 he still owns at least 92,085 units of Agenus Inc stock.

You can see the complete history of Mr. Corvese stock trades at the bottom of the page.





Brian Corvese biography

Brian J. Corvese serves as Independent Director of the Company. Since 1999, Mr. Corvese has been the President and Founder of Vencor Capital (“Vencor”), a private equity firm with telecommunications and technology investments in the Middle East and Mediterranean regions. Prior to working at Vencor, Mr. Corvese worked on investments in the U.S. and global equity markets as a Managing Director and partner at Soros Fund Management, the largest hedge fund in the world at the time. From 1988 to 1996, Mr. Corvese was a partner at Chancellor Capital Management (“Chancellor”), a $25 billion money management firm. While at Chancellor, Mr. Corvese was a Portfolio Manager with responsibility for investments made in basic industries, restructurings, and special situations, corporate governance investments, as well as founded and managed his own hedge fund. From 1981 to 1988, Mr. Corvese was with Drexel Burnham Lambert (“Drexel”) as an equity analyst following the chemical and specialty chemical industries and participated in a significant number of merger and acquisition activities. While at Drexel, Mr. Corvese was a member of the top chemical and specialty chemical research team, as ranked by Institutional Investor. Mr. Corvese currently serves on the Board of Directors of the National Telecommunications Corporation, based in Cairo, Egypt, and Protagenic Therapeutics based in Ontario, Canada. Mr. Corvese earned degrees in finance and political science from The University of Rhode Island and attended New York University Graduate School. With over 30 years of experience in the financial industry, Mr. Corvese brings substantial financial expertise to our Board.

What is the salary of Brian Corvese?

As the Independent Director of Agenus Inc, the total compensation of Brian Corvese at Agenus Inc is $662,141. There are 5 executives at Agenus Inc getting paid more, with Garo Armen having the highest compensation of $9,937,040.



How old is Brian Corvese?

Brian Corvese is 62, he's been the Independent Director of Agenus Inc since 2007. There are 4 older and 8 younger executives at Agenus Inc. The oldest executive at Agenus Inc is Wadih Jordan, 85, who is the Independent Director.

What's Brian Corvese's mailing address?

Brian's mailing address filed with the SEC is C/O AGENUS INC., 3 FORBES ROAD, LEXINGTON, MA, 02421.

Insiders trading at Agenus Inc

Over the last 23 years, insiders at Agenus Inc have traded over $24,466,328 worth of Agenus Inc stock and bought 13,248,226 units worth $63,837,873 . The most active insiders traders include Associates Gp Llcqvt Fund V..., Noubar Afeyan, and Corp Incyte. On average, Agenus Inc executives and independent directors trade stock every 99 days with the average trade being worth of $2,230,885. The most recent stock trade was executed by Garo H Armen on 15 February 2024, trading 500,000 units of AGEN stock currently worth $325,000.



What does Agenus Inc do?

agenus is an immunology company discovering and developing novel checkpoint modulators, vaccines and adjuvants to treat cancer and other diseases. we are a dedicated group of scientists, researchers, biotechnologists, physicians, and businesspeople working together toward one goal: to discover and develop therapies that can unleash the innate power of the body’s immune system to treat and potentially cure hard-to-treat cancers and other diseases. our product candidates are designed to work by educating and activating the body’s immune system for a precise and potent attack on cancer. our strategy is to help unlock the potential of one of the most exciting breakthrough areas in cancer treatment in decades, and to develop single agent and combination immune-oncology therapies that can help save lives. our approaches are driven by three platform technologies, including: • our antibody platforms, including our proprietary retrocyte display™ and secant® technologies, and our antibody



What does Agenus Inc's logo look like?

Agenus Inc logo

Complete history of Mr. Corvese stock trades at Agenus Inc

Date
#
Company
 Insider
Trans.
Transaction
 Shares Price per share Total value Shares after Source
16 Jun 2021 AGEN Agenus Inc Brian Corvese
Option 22,471 $100.00 $2,247,100
16 Jun 2021
92,085 ↗
19 Jun 2020 AGEN Agenus Inc Brian Corvese
Option 21,118 $76.60 $1,617,639
19 Jun 2020
69,614 ↗


Agenus Inc executives and stock owners

Agenus Inc executives and other stock owners filed with the SEC include: